Purpose: We studied the effects of intrathecal administration of an N-methyl-D-aspartate (NMDA) 
Objectif: Etudier l'influence de l'administration d'un antagoniste du rdcepteur N-mdthyl-D-aspartate (NMDA) et d'un antagoniste du site glycine du NMDA sur la concentration anesthdsique alvdolaire minimum (MAC) de l'isoflurane chez le rat anesthdsi~ et sur l'activit~ locomotrice chez le rat conscient. M~thodes: Chez des rats Wistar porteurs d'un cath~ter sousarachno'fdien implantgs, nous avons d~termin~ le MAC apr~s I' administration de solut~ physiologique (groupe contr5le); de l'antagoniste comp~titif du r~cepteur NMDA. l'acide 3-(2-carboxyperazine-4-yl)propyl-l-phosphonique (CPP) gt
More than 150 yr after the introduction of anaesthesia into clinical practice, the mechanisms and sites of action are unknown. Traditionally, we have believed the brain CAN J ANAESTH 1996 / 43:7 / pp724-30 to be a likely target site, specifically the cerebral cortex. With anaesthesia, we attempt to block consciousness, pain' perception and memory functions associated with supraspina!, areas ot; the central nervous .system. Accordingly, many experiments have been directed toward the assessment of anaesthetic effects on the cerebral cortex. Because of its presumed role. in memory formation and attentiveness, the hippocampus has been the focus of recent studies. ~ However, we, know that inhalational anaesthetics exert considerable effects elsewhere, such as at the spinal cord. 2,3 Anaesthetic agents at sufficient concentrations .depress excitatory transmission in the spinal cord. A recent, study in which the spinal cords of rats were transected, without altering MAC suggested that the relevant site fot, MAG determination was .in the spinal cord. reported that MAC in rats was unchanged after precollicular decerebratic.~n. Antognini et al. 6 reported that anaesthesia, as defined, by MAC, was not determinedby the cortex. Both re]ports suppo~ the:hypothesis that the potency of anaesthetics is determined by their actions in the midbrain, the brain stem., or the lower spinal :cord. The latter plays an important r'ole, in determining MAC,as defined in terms of :motor response to, a,noxious stimulus, most commonly a flexion'withdrawal reflex; mediated at the spinal, cord? 9 The role of excitatory amino acids (EAAs) in nociception is suggested by the fact that noxious stimuli cause the release of glutamate and aspartate in the spinal cord dorsal horn. 8,9 The EAAs act as transmitters ;in the spinal cord, especially in the superficial part of the dorsal horn.Intrathecal administration of,NMDA produces rapid, translient, dose-dependent hyperalgesia. 1~ This hyperalgesia is blocked by previous treatment with a selective NMDA receptor, antagonist, l~ It has also been shown that'the release of peptides and an amino acid neurotran'smitter from primary afferents is not sup-. pressed by inhalation anaesthetics.~2, 13 A recent study has shown that the systemic administration of NMDA antagonists reduces the MAC of isofl'uraneJ 4 In contrast, glycine potentiates the NMDA receptor ion channel complex, t5 and antagonism at the glycine, site on the NMDA receptor produced an antinociceptive action. 16 ~. We repo~'.ed that intrathecal administration of the competitive NMDA ,receptor antagonist APV (D-2-amino-5-phosphopentaoate) and noncompetitive antagonist MK801(dizocilpine) reduced the MAC of isofluraneJ 7 However, the intrathecal administration of NMDA receptor antagonists may produce a sedative effect. The first purpose of this study was to investigate the effect of intrathecal administration of the NMDA receptor antagonist CPP and the selective antagonist of the glycine site on the NMDA receptor complex 7CKA on the MAC of isoflurane. The second was to examine the effect on the, locomotor activity in conscious rats.
Methods
This investigation was conducted in accordance with a protocol approved by the Animal Care Committee of Gunma University. All of the experiments were performed using randomization and masking of drugs.
Animal preparation
Male Wistar rats (280-320 g) were fitted with indwelling intrathecal catheters using methods described previously, t8 In brief, the rats were mounted in a conventional stereotaxic instrument under halothane anaesthesia. A .middline incision was made on the skull, extending from a line between the ears to a point 2 cm caudal, and the fascia .and muscle were retracted from the skull and first vertebra. The atlanto-occipital membrane could be seen easily. When the incision was made correctly, there was a copious outwelling of clear cerebrospinal fluid. The indwelling intrathecal catheters were placed by passing a PE-10 catheter through an incision in the atlanto-occipital membrane to a position 8 cm caudal to the cisterna at .the level of the lumbar enlargement. The catheter was externalized on the top of the skull, and the wound .was closed with 3--0 silk sutures. We used only catheterized rats i.n which flaccid paralysis of the hindlimbs was observed after intrathecal administration of lidocaine 500 lag-10 lal-~; 19 on the day of surgery. Rats showing postoperative, neurological deficits, inflammation and weight' loss were killed with a barbiturate overdose. Measurement of .the MAC was carried out four to nine days after the intrathecal implantation of the catheter.
.. The agents studied were CPP (3-(2-carboxypiperazin-4-yl)propyl-l-phosphonic acid, Research Biochemical Inc), 7CKA (7-chlorokynurenic acid~ Sigma);. NMDA (N-methyl-D-aspartate, Sigma)~ and D-serine (2-amino-3hydropropanic acid; [3-hydroxy,lamine, Sigma). All drugs were dissolved in normal saline, so that the final dose was administered in a.volume ,of 10 lal. The animals were allocated randomly to eleven groups with six animals per group by a person who did not know the experimental protocol, including one control group and six NMDA antagonist groups; three groups received CPP 0.01-1 nM, and three groups received 7CKA 0.1-10 nM. After measurement of the MAC following administration of the antagonist, the equipotent reversal dose of NMDA 0.01-1 nM or D-serine 0.1-10 nM was administered regardless of whether MAC decreased. In another two groups, NMDA receptor antagonists CPP 0.1 nM and 7CKA 1 nM were reversed by various concentration of NMDA and D-serine, respectively. In the other two groups, rats with administered saline were treated with various concentration of NMDA and D-serine.
Measurement of MAC
Anaesthesia was induced with halothane 4% in oxygen by placing the rats in an induction chamber for three to five minutes. After tracheostomy, the trachea of each animal was intubated with a 14-G polyethylene catheter. The rats breathed spontaneously through a non-rebreathing circuit. The oxygen supply to the isoflurane vaporizer was keptat 2 L-min -t throughout the experiments. A polyethylene catheter (PE50) was inserted through the wall of the ventilatory tubing, and the tip of the sampiing tube was positioned distal to the tracheostomy; this arrangement permitted sampling of end-tidal gases and regulation of end-tidal COz by management of the oxygen escape valve. For blood pressure monitoring and blood sampling, one femoral artery was catheterized with a polyethylene catheter (PE50). Rectal temperature was maintained between 36.5 and 37.5~ by use of a heating pad and thermometer system (CMA150, Microdialysis AB, Stockholm, Sweden). The end-tidal concentration of isoflurane was measured with a calibrated infrared absorption instrument (ULTIMA, Datex Co., Helsinki, Finland). 2~ The analyzer was warmed up for at least 90 min before use and was calibrated with a standard calibration gas mixture.
The MAC of isoflurane was determined according to the up-and-down method using of the tail clamp technique. 7 After surgery, in each animal the lungs were ventilated initially for 20 min with isoflurane 1.5%. First, we injected saline to measure the standard MAC. A 20-cm rubber-shod haemostat was then applied with full ratcheted lock to the mid-portion of the rat's tail. The haemostat was applied continuously for 60 sec and then was removed. Any purposeful movement of the animal constituted a positive response, such as the movement of extremities, tail flick, or twitching. Nonpurposeful movements, such as stiffening, grimacing, and changing of respiratory patterns were disregarded. The isoflurane concentration was then adjusted by 10%, and drug was administered for 20 min at the new concentration before application of the haemostat was repeated. The subsequent position of the tail clamp was proximal to any previous site of application. The MAC was defined as the mean of the lowest concentration at which a negative response was observed plus the highest concentration at which a positive response was observed. After measurement of control values, CPP and 7CKA were infused intrathecally by the investigator who was blind to the drug used in the infusion. When the measurement of MAC of the NMDA receptor antagonists was completed, NMDA or D-serine was administered intrathecally. We performed a blood gas sample just before tail clamp.
Test of locomotor function
The rats were examined for the presence of locomotor dysfunction using the following methods. 2~ The NMDA receptor antagonists, NMDA and D-serine, were injected in the manner described above in 13 groups of five rats each. The experimenter did not know which drug was injected and the following tests were performed: 1 Placing reflex: The rat was held with the hindlimbs slightly lower than the forelimbs, and the dorsal surface of the hindpaws was brought into contact with the edge of a table. The experimenter recorded whether the hindpaws were placed on the table surface reflexively; 2 Grasping reflex: The rat was placed on a wire grid and the experimenter recorded whether the hindpaws grasped the wire upon contact; 3 Righting reflex: The rat was placed on its back on a flat surface and the experimenter noted whether it immediately assumed the normal upright position. Scores for placing, grasping and righting reflexes were based on counts of each normal reflex exhibited in five trials.
Statistical analysis
Statistical comparisons were made by ANOVA, and the Bonferroni method was applied for multiple comparisons. Wilcoxon's signed rank sum test was performed on the MAC values within each group. The level of statistical significance was defined as P < 0.05. The values are expressed as mean _+ SEM.
Results
The physiological variables were well controlled: there were no differences among the group (Tables I, II) . Body temperature remained unchanged during the experiment. Tables III and IV show the changes in the MAC of isoflurane. There were no differences among the seven groups with respect to baseline MAC values. At a CPP dose of 0.01 nM, three of six rats showed a decrease in MAC; at CPP doses 0.1 nM and 1.0 nM, all of the rats had a decrease in the MAC. At 0.1 nM and 1.0 nM, CPP produced decreases in the MAC of isoflurane ranging from 9.9-17.6% of control values (P < 0.05). Administration of NMDA reversed the decreases MAP (mmHg) 108 (5) 115 (5) 112 (8) 116 (5) 118 (5) 116 (7) 118(6) Heart rate (bpm)
353 (22) 365 (7) 368 (13) 359 (9) 387 (15) 391 (20) 372 (18) PaO2 (mmHg) 389 (20) 406 (22) 405 (27) 319 (40) 379 (20) 404 (10) 371 ( in the MAC of isoflurane (Table III) . Two of six rats showed a decrease in MAC at a dose of 0.1 nM, 7CKA. When given at 1.0 nM and 10 nM, 7CKA caused MAC to decrease 10.5-15.5% of control values (P < 0.05).
Intrathecal administration of D-serine reversed the decreases in MAC (Table IV) . Reversal effects of NMDA occurred at a CPP dose 0.1 nM and of D-serine at a 7CKA dose 1.0 nM (Table V, VI) . NMDA and D-serine did not increase the MAC of isoflurane. There were no differences between groups of the effects of the agents on locomotor function (Table VII) . Convulsions and hypermobility were not observed in association with CPP+NMDA or 7CKA+D-serine.
Discussion
Physiological variables were well controlled, and body temperature remained stable. We regulated the PaCO2 by managing the escape flow; PaCO2 did not change during the experiment. There were no factors that influenced the MAC of isoflurane other than the NMDA receptor antagonists. 22 Administration of an NMDA receptor antagonist and an antagonist of the glycine site decreased the MAC of isoflurane, but this was reversed by the administration of NMDA and D-serine. It has been proposed that the NMDA receptor is related to the MAC of inhalation anaesthetics) 4'17 The degree of reduction in MAC was similar to that obtained with intrathecal administration of the competitive NMDA receptor antagonist APV and noncompetitive antagonist MK801) 7 The competitive NMDA receptor antagonist CPP directly blocks the glutamate recognition site and CPP is a more potent NMDA receptor antagonist than APV. Kirstensen et al. 23 reported that CPP had antinociceptive effects in three different nociceptive tests: a tail-flick, a hot-plate, and a formalin test. The action of glycine seems to be mediated via an allosteric recognition site on the NMDA receptor. It has been demonstrated that responses evoked by NMDA in cultured neurons can be potentiated by glycine) 5 Glycine modulates the NMDA system not only at the supraspinal level but also at the spinal level. Intrathecal administration in a rat model is common. However, there are many problems with the use of this model. We excluded rats with nerve injury, inflammation and weight loss after insertion of the catheter. The MAC was influenced by these events. We measured body weight and monitored inflammation in the suture region and MAC was stable on days four to nine. We used only catheterized rats in which flaccid paralysis of the hindlimbs was observed just after intrathecal administration of lidocaine 500 ~tg. 10 lal -~ on the day of surgery) 9 It is important to place the catheter correctly. When the catheter tip was in a good position, we were able to see the paralysis just after injection. If the drug was injected into the epidural space, paralysis was observed 20 min later.
The intrathecal administration of NMDA receptor antagonists may produce a sedative effect and MK801 and APV cause ataxia, sedation and anaesthesia. 26 Kurode et al, 14 reported that systemical administration of NMDA receptor antagonists decreases-MAC of isoflurane by 50%. According to this report, the investigators used neuroprotective doses of NMDA receptor antagonists. Administration of NMDA receptor antagonists at a dose of 17.8 mM,kg -~ (one million times higher than our doses) produces some adverse effects, such as atax.ia, :perceptual disorders, sedation, anaesthesia, and psychotomimetic effects. We believe that the sedative effect decreased the MAC of isoflurane:in previous experiments, and therefore, used an antinociceptive dose without sedative effects in this study. The degree of reduction in the MAC was small compared with that obtained with systemical administration of neuroprotective doses.
Administration of NMDA receptor antagonists causes motor nerve dysfunction and CPP produces motor nerve dysfunction at a doses of 10 nM. 23 Coderre et al. 2~ reported that 7CKA also caused disruption of the placing reflex at a dose of 18 nM. Motor nerve paralysis produced by NMDA receptor antagonists could reflect an increase in extensor tone produced by a reduction in post-synapt~ic inhibition of motor neurons following antagonism of synaptic excitation of Renshaw cells or other interneurons. 27 A locomotor test did not reveal motor weakness in our experiment.
When NMDA is administered intrathecally in the mouse, it elicits dose-related, caudally directed biting and scratching behaviour. However, this hyperalgesia is blocked by previous treatment with a selective NMDA receptor antagonist. ~t We injected NMDA following the administration of an NMDA receptor antagonist and did not observe convulsions or hypermobility.
There are some problems in using NMDA receptor antagonists in clinical practice. Competitive NMDA receptor antagonists such as CPP and APV do not easily cross the blood-brain barrier, so clinical administration is limited. Noncompetitive NMDA receptor antagonists such as ketamine and MK801 produce psychotomimetic effects at a higher dose levels. 26 In contrast, antagonists of the glycine site of the NMDA receptor complex easily cross the blood-brain barrier and produce potent NMDA rece.ptor antagonism at doses that do not produce neurotoxic or behaviour stimulant effects. 21 Antagonists of the glycine site on the NMDA receptor complex may be used with a lowered risk of undesired side effects. The only NMDA receptor antagonist licensed for use in patients is the dissociative anaesthetic ketamine, which is unpleasant for most patients when given systemically. Nevertheless, epidural ketamine produces potent postoperative analgesia. 2s Ketamine probably produces its analgesic effects by disrupting sensory input in the spinal cord and thalalTlUS. 29 There is evidence that wind-up is dependent on NMDA receptor activation 3~ and that NMDA receptor antagonists may prevent behaviour indicative of pain.3t'This experiment suggest a new possibility that NMDA receptor antagonist, s decrease the need for inhalational anaesthetics and reduce postoperative pain with no unacceptable side effects. Further investigation is necessary before NMDA receptor antagonists are accepted for clinical use.
In summary, the MAC of isoflurane is depressed by intrathecal administration of the competitive NMDA receptor antagonist CPP and the antagonist of the glycine site on the NMDA receptor 7CKA.
Intrathecal administration of NMDA or D-serine reversed the decreases in MAC to control values. Locomotion activity is not changed.
